drugset / Trial / NCT03451487

A Randomized, Single-blind, Parallel Group and Multiple - Dose Design Study

NCT03451487

Completed 28 enrolled Sinew Pharma Inc.
RandomizedParallel-groupSingle-blindOther

Summary

To investigate and compare the possible response of Panadol® and SafeTynadol® formulations in healthy volunteers.

Timeline

Start
2022-05-19
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule 1000 mg Oral
Comparator Acetaminophen Small molecule 4000 mg Oral
Subject SafeTynadol Unknown 1000 mg Oral
Subject SafeTynadol Unknown 4000 mg Oral

Indications